Some studies have shown that patients with hepatitis C are at increased risk of cardiovascular disease based on increased carotid intima-media thickness.(4) These increases in markers of early atherosclerosis in chronic hepatitis-C may make 3-hydroxy -3-methylglutaryl coenzyme A reductase inhibitors (statins) of a particular benefit in this patient population. Statins have a central role in the treatment of hypercholesterolemia and have proven to be the most efficacious drug therapy for attaining significant reductions in low- density lipoprotein cholesterol levels.